Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Interchangeable Biosimilar Designations Shouldn't Be Forever, Innovators Say

Jun 01 2017

• By Sue Sutter

Related Content

Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability

Jan 18 2017

Next Steps For Interchangeable Biosimilars: Lifecycle Regulation Policy Development

Jan 18 2017

US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry

Jun 01 2017

Biosimilar Switching Studies, Human Factors Analyses Are Flashpoints For Industry

Jun 01 2017

Related Companies

Amgen, Inc.

Johnson & Johnson

Additional Topics

United States Biosimilars Drug Approval Standards Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window